GSK’s Witty Speaks Further On M&A, Pricing
This article was originally published in The Pink Sheet Daily
U.K. pharma giant’s growth will come from a diversified, innovative portfolio of medicines, emerging markets, vaccines, and “bolt-ons.”
You may also be interested in...
Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.
Pfizer’s Mikael Dolsten, Bristol’s Francis Cuss and GSK’s Andrew Witty gave updates on their companies’ progress and direction at the Citi Global Healthcare Conference. Immuno-oncology was a common thread in Dolsten and Cuss’ comments, while Witty talked about GSK’s revised pricing strategies.
With eighteen months until the start of a new drug pricing scheme, the slow progress and lack of detail on the U.K.'s value-based pricing (VBP) approach worries industry and suggests transitional arrangements may be necessary.